Antithrombotic Regimens for Patients Taking Oral Anticoagulation after Coronary Intervention: A Meta-analysis of 16 Clinical Trials and 9185 Patients

Clinical Cardiology

Volumn 38, Issue 8, 2015, Pages 499-509

  Gao, Xiao Fei ^a,b   Chen, Yan ^a   Fan, Zhong Guo ^a   Jiang, Xiao Min ^a   Wang, Zhi Mei ^a   Li, Bing ^a   Mao, Wen Xing ^a   Zhang, Jun Jie ^a,b   Chen, Shao Liang ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Nanjing Heart Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN ISCHEMIA; COCHRANE LIBRARY; CORONARY STENTING; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEART DISEASE; HEART INFARCTION; HUMAN; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RISK REDUCTION; STENT THROMBOSIS; THROMBOSIS; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; FEMALE; MALE; TREATMENT OUTCOME;

ANTICOAGULANTS; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT OUTCOME;

EID: 84939466868     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22411     Document Type: Review

References (38)

1. Connolly S, Pogue J, Hart R, et al,; ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367: 1903-1912.
2. Camm AJ, Lip GY, De Caterina R, et al., 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association [published corrections appear in Eur Heart J. 2013;34:790 and Eur Heart J. 2013;34:2850-2851]. Eur Heart J. 2012; 33: 2719-2747.
3. Nabauer M, Gerth A, Limbourg T, et al., The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009; 11: 423-434.
4. DeEugenio D, Kolman L, DeCaro M, et al., Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy. 2007; 27: 691-696.
5. Khurram Z, Chou E, Minutello R, et al., Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol. 2006; 18: 162-164.
6. Ruiz-Nodar JM, Marín F, Hurtado JA, et al., Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008; 51: 818-825.
7. Manzano-Fernández S, Pastor FJ, Marín F, et al., Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest. 2008; 134: 559-567.
8. Gao F, Zhou YJ, Wang ZJ, et al., Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. Int J Cardiol. 2011; 148: 96-101.
9. Zhao HJ, Zheng ZT, Wang ZH, et al., "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest. 2011; 139: 260-270.
10. Lip GY, Huber K, Andreotti F, et al,; European Society of Cardiology Working Group on Thrombosis. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary-a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010; 31: 1311-1318.
11. Faxon DP, Eikelboom JW, Berger PB, et al., Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North American perspective. Thromb Haemost. 2011; 106: 572-584.
12. Dewilde WJ, Oirbans T, Verheugt FW, et al,; WOEST Study Investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013; 381: 1107-1115.
13. Seivani Y, Abdel-Wahab M, Geist V, et al., Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Clin Res Cardiol. 2013; 102: 799-806.
14. Lamberts M, Gislason GH, Olesen JB, et al., Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013; 62: 981-989.
15. Rubboli A, Schlitt A, Kiviniemi T, et al,; AFCAS Study Group. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. Clin Cardiol. 2014; 37: 357-364.
16. January CT, Wann LS, Alpert JS, et al., 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published correction appears in J Am Coll Cardiol. 2014;64:2305-2307]. J Am Coll Cardiol. 2014; 64: e1-e76.
17. Liberati A, Altman DG, Tetzlaff J, et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009; 151: W65-W94.
18. Egger M, Davey Smith G, Schneider M, et al., Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634.
19. Gilard M, Blanchard D, Helft G, et al,; STENTICO Investigators. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from Stenting and Oral Anticoagulants [STENTICO]). Am J Cardiol. 2009; 104: 338-342.
20. Sarafoff N, Ndrepepa G, Mehilli J, et al., Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med. 2008; 264: 472-480.
21. Mattichak SJ, Reed PS, Gallagher MJ, et al., Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction. J Interv Cardiol. 2005; 18: 163-166.
22. Rossini R, Musumeci G, Lettieri C, et al., Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008; 102: 1618-1623.
23. Rubboli A, Saia F, Sciahbasi A, et al,; Warfarin and Coronary Stenting (WAR-STENT) Study Group. Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. J Invasive Cardiol. 2014; 26: 563-569.
24. Karjalainen PP, Porela P, Ylitalo A, et al., Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007; 28: 726-732.
25. Sambola A, Ferreira-González I, Angel J, et al., Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study. Heart. 2009; 95: 1483-1488.
26. Fosbol EL, Wang TY, Li S, et al., Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. Am Heart J. 2013; 166: 864-870.
27. Nguyen MC, Lim YL, Walton A, et al,; GRACE Investigators. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? Eur Heart J. 2007; 28: 1717-1722.
28. McNamara RL, Tamariz LJ, Segal JB, et al., Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med. 2003; 139: 1018-1033.
29. Lip GY, Hart RG, Conway DS,. Antithrombotic therapy for atrial fibrillation. BMJ. 2002; 325: 1022-1025.
30. Hart RG, Pearce LA, Aguilar MI,. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857-867.
31. Doyle BJ, Rihal CS, Gastineau DA, et al., Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol. 2009; 53: 2019-2027.
32. Chhatriwalla AK, Amin AP, Kennedy KF, et al., Association between bleeding events and in-hospital mortality after percutaneous coronary intervention [published correction appears in JAMA. 2013;310:647]. JAMA. 2013; 309: 1022-1029.
33. Fuster V, Ryden LE, Cannom DS, et al., ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) [published correction appears in J Am Coll Cardiol. 2007;50:562]. J Am Coll Cardiol. 2006; 48: 854-906.
34. Rodriguez-Leor O, Fernandez-Nofrerias E, Carrillo X, et al., Transradial percutaneous coronary intervention in cardiogenic shock: a single-center experience. Am Heart J. 2013; 165: 280-285.
35. Yang YJ, Kandzari DE, Gao Z, et al., Transradial versus transfemoral method of percutaneous coronary revascularization for unprotected left main coronary artery disease: comparison of procedural and late-term outcomes. JACC Cardiovasc Interv. 2010; 3: 1035-1042.
36. Dewilde WJ, Janssen PW, Verheugt FW, et al., Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review. J Am Coll Cardiol. 2014; 64: 1270-1280.
37. Pisters R, Lane DA, Nieuwlaat R, et al., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093-1100.
38. Reed GW, Cannon CP,. Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting. Clin Cardiol. 2013; 36: 585-594.